Repligen Corporation is a global life sciences company that develops and commercializes bioprocessing technologies and systems. Its focus areas are Filtration and Fluid Management, Chromatography, Process Analytics and Proteins. Its filtration products are used in process development and process scale (clinical and commercial) production. Its XCell ATF systems are used in upstream perfusion (continuous) and N-1 (intensified fed-batch or hybrid perfusion) cell culture processing. Its chromatography franchise includes several products used in downstream purification, development, manufacturing and quality control of biological drugs. Its process analytics products complement and support its filtration, chromatography and protein franchises. Its TangenX product portfolio includes flat sheet (FS) tangential flow filtration (TFF) cassettes used primarily in downstream and ultrafiltration processes. Its desktop portfolio includes MAVERICK and MAVEN, REBEL, and ZipChip.
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRGEN
āļāļ·āđāļāļāļĢāļīāļĐāļąāļRepligen Corp
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 29, 1986
āļāļĩāļāļĩāđāļMr. Olivier Loeillot
āļāļģāļāļ§āļāļāļāļąāļāļāļēāļ1778
āļāļĢāļ°āđāļ āļāļāļēāļĢāļĢāļąāļāļĐāļēāļāļ§āļēāļĄāļāļĨāļāļāļ āļąāļĒOrdinary Share
āļŠāļīāđāļāļāļĩāļāļāļāļĢāļ°āļĄāļēāļApr 29
āļāļĩāđāļāļĒāļđāđBuilding 1, Suite 100
āđāļĄāļ·āļāļWALTHAM
āļāļĨāļēāļāļŦāļĨāļąāļāļāļĢāļąāļāļĒāđNASDAQ Global Select Consolidated
āļāļĢāļ°āđāļāļĻUnited States of America
āļĢāļŦāļąāļŠāđāļāļĢāļĐāļāļĩāļĒāđ02453
āđāļāļĢāļĻāļąāļāļāđ17814499560
āđāļ§āđāļāđāļāļāđhttps://www.repligen.com/
āļŠāļąāļāļĨāļąāļāļĐāļāđāļĒāđāļāļāļāļāļŦāļļāđāļRGEN
āļ§āļąāļāļāļĩāđāđāļŠāļāļāļāļēāļĒāļāļĢāļąāđāļāđāļĢāļApr 29, 1986
āļāļĩāļāļĩāđāļMr. Olivier Loeillot
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
Mr. Glenn P. Muir
Independent Director
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Mr. Rohin Mhatre, Ph.D.
Independent Director
Dr. Konstantin Konstantinov, Ph.D.
Dr. Konstantin Konstantinov, Ph.D.
Independent Director
Mr. Jason K. Garland
Chief Financial Officer
Mr. Tony John Hunt
Executive Chairman of the Board
Executive Chairman of the Board
Dr. Martin D. Madaus, Ph.D.
Dr. Martin D. Madaus, Ph.D.
Independent Director
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Ms. Karen A. Dawes
Lead Independent Director
Lead Independent Director
Mr. Glenn P. Muir
Independent Director
Mr. Olivier Loeillot
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
Mr. Ralf Kuriyel
Senior Vice President - Research and Development
Senior Vice President - Research and Development
Mr. Nicolas M. Barthelemy
Mr. Nicolas M. Barthelemy
Independent Director
Mr. Rohin Mhatre, Ph.D.
Independent Director
First Trust NYSE Arca Biotechnology Index Fund
Invesco Biotechnology & Genome ETF
BNY Mellon Innovators ETF
iShares Health Innovation Active ETF
Franklin Genomic Advancements ETF
WisdomTree BioRevolution Fund
Pacer US Export Leaders ETF
āļāļđāđāļāļīāđāļĄāđāļāļīāļĄ
Alger Mid Cap 40 ETF
āļŠāļąāļāļŠāđāļ§āļ4.16%
First Trust NYSE Arca Biotechnology Index Fund
āļŠāļąāļāļŠāđāļ§āļ3.18%
Invesco Biotechnology & Genome ETF
āļŠāļąāļāļŠāđāļ§āļ2.7%
BNY Mellon Innovators ETF
āļŠāļąāļāļŠāđāļ§āļ2.6%
iShares Health Innovation Active ETF
āļŠāļąāļāļŠāđāļ§āļ1.64%
VanEck Biotech ETF
āļŠāļąāļāļŠāđāļ§āļ1.39%
Franklin Genomic Advancements ETF
āļŠāļąāļāļŠāđāļ§āļ1.24%
Congress SMid Growth ETF
āļŠāļąāļāļŠāđāļ§āļ1.24%
WisdomTree BioRevolution Fund
Pacer US Export Leaders ETF
āļŠāļąāļāļŠāđāļ§āļ0.93%
āļĄāļĩāļāļēāļĢāļāđāļēāļĒāđāļāļīāļāļāļąāļāļāļĨāđāļāđāļāļāļģāļāļ§āļāļĢāļ§āļĄ
0.00
USD āđāļāļāđāļ§āļ 5 āļāļĩāļāļĩāđāļāđāļēāļāļĄāļē

āđāļĄāđāļĄāļĩāļāđāļāļĄāļđāļĨ